CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+6.21%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$907M
AUM Growth
+$907M
(+28%)
Cap. Flow
+$198M
Cap. Flow
% of AUM
21.86%
Top 10 Holdings %
Top 10 Hldgs %
37.32%
Holding
435
New
22
Increased
337
Reduced
40
Closed
7
Top Buys
| 1 |
Apple
AAPL
|
$25.8M |
| 2 |
Broadcom
AVGO
|
$24.2M |
| 3 |
Microsoft
MSFT
|
$10.9M |
| 4 |
Amgen
AMGN
|
$7.28M |
| 5 |
NVIDIA
NVDA
|
$6.87M |
Top Sells
| 1 |
Micron Technology
MU
|
$6.44M |
| 2 |
ServiceNow
NOW
|
$5.1M |
| 3 |
Salesforce
CRM
|
$5M |
| 4 |
CrowdStrike
CRWD
|
$4.33M |
| 5 |
Qualcomm
QCOM
|
$3.38M |
Sector Composition
| 1 | Technology | 37.6% |
| 2 | Healthcare | 28.11% |
| 3 | Consumer Discretionary | 12.57% |
| 4 | Communication Services | 9.53% |
| 5 | Consumer Staples | 3.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Wave Life Sciences
WVE
$1.53B
| $197K | 0.02% |
23,991
+9,603
| +67% | +$78.7K |
|
302
Genmab
GMAB
$15.9B
| $197K | 0.02% |
8,064
+3,137
| +64% | +$76.5K |
|
303
Evolus
EOLS
$485M
| $197K | 0.02% |
12,135
+4,780
| +65% | +$77.4K |
|
304
Kiniksa Pharmaceuticals
KNSA
$2.54B
| $195K | 0.02% |
7,810
+3,076
| +65% | +$76.9K |
|
305
AnaptysBio
ANAB
$577M
| $195K | 0.02% |
5,808
+2,600
| +81% | +$87.1K |
|
306
Zoetis
ZTS
$67.8B
| $193K | 0.02% |
986
| – | – |
|
307
Dollar Tree
DLTR
$23.2B
| $192K | 0.02% |
2,726
+1,414
| +108% | +$99.4K |
|
308
Autoliv
ALV
$9.55B
| $187K | 0.02% |
2,000
| – | – |
|
309
Cullinan Oncology
CGEM
$442M
| $187K | 0.02% |
11,151
+4,380
| +65% | +$73.3K |
|
310
Relay Therapeutics
RLAY
$631M
| $182K | 0.02% |
25,751
+10,157
| +65% | +$71.9K |
|
311
Sana Biotechnology
SANA
$721M
| $178K | 0.02% |
42,787
+16,764
| +64% | +$69.7K |
|
|
PETQ
312
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $175K | 0.02% |
5,703
+2,233
| +64% | +$68.7K |
|
313
Prothena Corp
PRTA
$445M
| $173K | 0.02% |
10,344
+4,026
| +64% | +$67.4K |
|
314
Zymeworks
ZYME
$1.06B
| $171K | 0.02% |
13,665
+5,359
| +65% | +$67.3K |
|
315
Invesco QQQ Trust
QQQ
$361B
| $164K | 0.02% |
335
-745
| -69% | -$364K |
|
316
Veeva Systems
VEEV
$44.1B
| $162K | 0.02% |
771
| – | – |
|
|
BCYC
317
Bicycle Therapeutics
BCYC
$499M
| $162K | 0.02% |
7,138
+2,918
| +69% | +$66K |
|
318
Carnival Corp
CCL
$42.2B
| $159K | 0.02% |
8,617
| – | – |
|
319
Tango Therapeutics
TNGX
$741M
| $159K | 0.02% |
20,607
+8,055
| +64% | +$62K |
|
320
Castle Biosciences
CSTL
$702M
| $152K | 0.02% |
5,335
+2,093
| +65% | +$59.7K |
|
321
89bio
ETNB
$1.36B
| $151K | 0.02% |
20,370
+8,810
| +76% | +$65.2K |
|
322
Erasca
ERAS
$454M
| $148K | 0.02% |
54,335
+23,808
| +78% | +$65K |
|
323
AbCellera Biologics
ABCL
$1.21B
| $147K | 0.02% |
56,674
+22,128
| +64% | +$57.5K |
|
324
Adaptive Biotechnologies
ADPT
$1.96B
| $145K | 0.02% |
28,364
+11,050
| +64% | +$56.6K |
|
325
Replimune Group
REPL
$461M
| $144K | 0.02% |
13,140
+5,926
| +82% | +$64.9K |
|